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Abstract
Background: We have recently shown that the transjugu-
lar intrahepatic portosystemic shunt (TIPS) is more effec-
tive than paracentesis in the treatment of cirrhotic pa-
tients with severe ascites and can prolong survival in
selected patients. Although an improved quality of life
(QOL) has been suggested in these patients after the
TIPS procedure, so far there are no data available to sub-
stantiate this assumption. Therefore, the aim of this
study was to determine the effect of TIPS on the QOL in
cirrhotic patients with refractory or recidivant ascites.
Methods: 21 cirrhotic patients who underwent TIPS for
refractory or recidivant ascites were investigated. All
patients were pretreated with repeated paracentesis for
at least 1 year. Before the procedure and at 3 and 6
months during follow-up, the patients themselves rated
QOL, fatigue and physical performance on a visual ana-
logue scale (range 0–100). Furthermore, QOL was deter-
mined by the QOL index (range 0–10) according to Spitz-
er. Results: Patients’ rating of the QOL on the visual ana-
logue scale significantly increased from 35 B 25 (base-
line) to 64 B 28 (3 months), and 66 B 24 (6 months; p =
0.02). Similarly, the QOL index significantly increased
from 6.9 B 2.0 (baseline) to 8.3 B 2.1 (3 months), and 8.6
B 1.7 (6 months; p ! 0.001). The increase of QOL was
more pronounced in patients with complete response to
TIPS. Conclusions: We demonstrate that TIPS for refrac-
tory or recidivant ascites improves the QOL in patients
with cirrhosis. Our data indicates that this improvement
is dependent on the response to therapy.
Copyright © 2002 S. Karger AG, Basel
Introduction
The transjugular intrahepatic portosystemic shunt
(TIPS) improves renal function in patients with refractory
ascites [1]. This effect can be observed in cirrhotic patients
with functional renal failure and in patients with underly-
ing organic renal failure [2]. It explains the positive
influence of TIPS on the mobilization of refractory ascites
in cirrhotic patients [3]. Recently, in a randomized con-
trolled trial, we demonstrated a beneficial effect of TIPS on
ascites and survival in patients with refractory or recidi-
vant ascites as compared to treatment with repeated para-
centesis [4]. Furthermore, patients treated with TIPS in
this study tended to spend less time in hospital. These and
similar observations [5] suggest an improved quality of life
(QOL) after the TIPS procedure. However, there is only
scarce information [6] to substantiate this assumption.
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Table 1. Characteristics of the 21 patients
receiving TIPS and follow-up of liver
function after TIPS placement
Baseline 3 months 6 months
Sex, m/f 18/3 – –
Age, years 56B4 – –
Aetiology of cirrhosis, alcohol/viral/other 15/4/2 – –
Child-Pugh class, A/B/C 0/17/4 1/18/2 3/17/1
Serum bilirubin, mg/dl 1.9B1.1 2.1B1.5 1.9B1.6
Serum albumin, g/dl 3.3B0.5 3.4B0.7 3.6B0.6
Prothrombin index, % 62B8 59B9 65B7
Serum sodium, mmol/l 129B7 133B5 134B4
Serum creatinine, mg/dl 1.4B0.4 1.2B0.3 1.2B0.4
Duration of intervention, min 73B8
The aim of the present study was therefore to measure
the QOL of cirrhotic patients with refractory or recidivant
ascites treated with TIPS.
Patients and Methods
Patients
After the end of the randomized trial comparing TIPS and para-
centesis [4], 21 consecutive cirrhotic patients who underwent TIPS
for refractory or recidivant ascites were investigated. Patient charac-
teristics are shown in table 1. The diagnostic criteria of the Interna-
tional Ascites Club [7] were applied for refractory or recidivant
ascites. All patients considered for TIPS were pretreated by repeated
paracenteses with intravenous albumin infusion for at least 1 year.
Patients with alcoholic cirrhosis were considered for the TIPS proce-
dure when they had abstained from alcohol consumption for at least
3 months. Alcohol consumption was evaluated by questioning upon
each visit and to the best of our knowledge all patients abstained
from alcohol during the study period. TIPS was not considered for
patients with hepatic encephalopathy grade 2 or higher and/or for
patients with serum bilirubin concentrations 15 mg/dl. Further
exclusion criteria comprised presence of hepatocellular carcinoma or
severe congestive heart failure.
Protocol and QOL Assessment
The study protocol was approved by the Ethics Committee of the
Faculty of Medicine at the University of Munich. Each patient gave
informed written consent to participate in the study. The TIPS pro-
cedure was performed as described earlier in detail [1, 4]. All inter-
ventions were performed under analgesia using 5–10 mg midazolam
and 15–30 mg pentazocine. Lactulose was routinely administered in
all patients after TIPS to induce 1–2 loose stools per day. Diuretic
drugs were dispensed as necessary.
Patients themselves rated QOL (0 very bad, 100 excellent),
fatigue (0 not tired at all, 100 very tired), and physical performance
(0 very bad, 100 excellent) on a visual analogue scale (visual analogue
scale) before the procedure and at 1, 3 and 6 months during follow-
up. Since all patients had been pretreated with paracentesis for at
least 1 year, baseline values were considered as representative for
patients undergoing paracentesis.
Furthermore, the QOL of each patient was rated on the QOL
index (range 0–10) according to Spitzer et al. [8]. Briefly, 5 items,
namely activity, daily living, health perception, support and outlook
on life were rated 0–2 in a structured interview performed by a health
professional. Hepatic encephalopathy was graded clinically accord-
ing to neuropsychiatric signs [9]: grade 0 – no evidence for hepatic
encephalopathy, grade 1 – patient confused with altered mood and/
or behaviour, grade 2 – inappropriate behaviour, drowsiness, grade
3 – stuporous patients with marked confusion, grade 4 – coma.
A complete response to TIPS was defined as the elimination of
ascites, and a partial response as the presence of ascites not requiring
paracentesis. Absence of a response was defined as the persistence of
refractory ascites.
Statistical Analysis
Data are given as mean B SE and were compared by ANOVA or
t-test, where appropriate. A p value !0.05 was considered statistical-
ly significant.
Results
All patients included could be evaluated at 3 and 6
months of follow-up. None of the patients had to be
excluded from analysis due to inability of completing
QOL assessment.
At 3 months of follow-up, 6 patients showed complete
response to TIPS, 9 patients had partial response and 6
patients were classified as non-responders. At 6 months, 7
patients were devoid of ascites, 10 patients showed partial
response and 4 patients were classified as non-respond-
ers.
The QOL index significantly increased from 6.9 B 2.0
(baseline) to 8.3 B 2.1 (3 months), and 8.6 B 1.7 (6
months; p ! 0.001). Similarly, patients’ rating of the QOL
on the visual analogue scale significantly increased from
35 B 25 (baseline) to 64 B 282 (3 months), and 66 B 24
(6 months; p = 0.02; table 2).
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Table 2. Effect of TIPS on the QOL index and self-assessment of patients’ QOL using a visual analogue scale
All patients
(n = 21)
CR 3 months
(n = 6)
PR 3 months
(n = 9)
NR 3 months
(n = 6)
CR 6 months
(n = 7)
PR 6 months
(n = 10)
NR 6 months
(n = 4)
QOL index
Baseline
3 months
6 months
6.9B2.0
8.3B2.1a
8.6B1.7a
6.5B1.2
9.7B0.6b
7.2B1.0
8.1B1.0
6.5B2.5
7.1B0.7
6.8B1.5
9.4B0.7b
7.0B1.0
8.4B0.8
6.5B2.6
7.0B1.0
Visual analogue scale QOL
Baseline
3 months
6 months
35B25
64B28a
66B24a
34B10
88B12b,c
42B13
57B11
35B15
48B16
37B8
75B14b
40B13
67B6
35B17
42B25
CR = Complete response; PR = partial response; NR = non-responder.
a p ! 0.05 by ANOVA as compared to baseline; b p ! 0.05 by paired t-test as compared to baseline; c p ! 0.05 by ANOVA as compared to
NR 3 months.
These changes were more pronounced in patients with
complete response to TIPS than in patients with partial
response or non-responders: in patients with complete
response after 3 months the QOL index increased by 3.1
B 0.6 as compared to 0.9 B 1.0 in patients with partial
response (p ! 0.05) and to 0.6 B 1.4 in non-responders
(p ! 0.05). After 6 months this increase was significantly
higher in patients with complete response (2.6 B 0.7)
than in non-responders (0.5 B 1.7; p ! 0.05).
Similarly, there was a significantly higher increase of
the complete responders’ rating of their QOL after 3
months (55 B 11) as compared to the rating of patients
with partial response (15 B 12; p ! 0.05) or compared to
non-responders (13 B 4; p ! 0.05). After 6 months, this
increase was significantly higher in complete responders
(40 B 16; non-responders 7 B 20; p ! 0.05).
The grade of hepatic encephalopathy before TIPS was
0.6 B 0.1 and did not significantly change after 3 months
(0.3 B 0.2), and 6 months (0.3 B 0.2). Accordingly, TIPS
did not significantly affect the patients’ visual analogue
scale rating of fatigue (25 B 7 before TIPS) after 3 months
(25 B 6), and 6 months (27 B 8), respectively.
Discussion
The present study provides the following main results:
(1) TIPS for refractory or recidivant ascites improves the
QOL in patients with cirrhosis, and (2) the improvement
of the patients’ QOL depends on the response to treat-
ment.
Fig. 1. Changes of the QOL 6 months after TIPS for refractory
ascites as assessed by the QOL index (QLI; black bars) and the
patients’ rating of their QOL on a visual analogue scale (VAS;
hatched bars). The improvement was significantly higher in com-
plete responders (CR) as compared to patients with partial response
to TIPS (PR) or non-responders (NR).
Recently, we have shown that TIPS is an effective treat-
ment in selected patients with refractory or recidivant
ascites [4]. Although an improved QOL has been suggested
after the TIPS procedure [5], so far only one study
addressed this issue in cirrhotic patients undergoing TIPS
for prophylaxis of variceal rebleeding or treatment of
ascites, eventually suggesting an improved QOL after TIPS
[6]. In this study, however, QOL was assessed using the
Karnofsky index [10] referring to an interpretation of QOL
restricted to physical performance status. Its coverage of
the conceptual domain necessary for a QOL scale has been
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deemed inadequate [11]. Consequently, it should be only
utilized measuring physical activity levels [12].
Given the encouraging results from our previous ran-
domized trial [4] we did not include a control group of
patients who had to continue paracentesis for refractory
ascites. One might thus argue that the present study is not
controlled. However, all patients included in the present
investigation had been pretreated with repeated paracen-
teses for at least 1 year. Therefore, baseline values of QOL
assessment can be regarded as the control values for
patients undergoing paracentesis, thus each patient serv-
ing as his own control.
To measure QOL we employed the Spitzer QOL index.
This is a concise instrument based on evaluation of 5
equally weighted items related to the patients’ mood, per-
ception of health, self-care ability, daily activity and social
interaction with family or friends [10]. Using this index
we could demonstrate an increase of the QOL of cirrhotic
patients with ascites after TIPS. This was constant at 3
and 6 months of follow-up. Importantly, the increasing
values of the QOL index were paralleled by increasing
QOL as rated by the patients themselves on a visual ana-
logue scale. Interestingly, these changes were more pro-
nounced in patients showing complete response to thera-
py than in patients with only partial response or non-
responders. These findings suggest that the influence of
TIPS on the patients’ QOL is dependent on removal of
ascites without the need for further paracentesis [13].
Interestingly, partial response was associated with only
slight improvement of QOL. In our view this indicates
that QOL of patients with ascites may not only be
influenced by the invasiveness of repeated therapeutic
procedures such as paracentesis, but also by the presence
(or absence) of ascites which may cause significant ab-
dominal discomfort.
An important factor influencing the overall QOL in
patients after TIPS is the incidence of hepatic encepha-
lopathy [14]. In the present study, we did not observe a
significant change of the grade of encephalopathy during
follow-up. This seems important since encephalopathy
may affect the accuracy of patients’ rating of QOL. This
was confirmed by the patients’ rating of fatigue on a visual
analogue scale. These findings are in accordance with our
previous observation that incidence of encephalopathy is
not higher in cirrhotic patients after TIPS as compared to
cirrhotic patients treated with paracentesis [4]. Our data
strengthens the advantage of TIPS over surgical shunts
where severe encephalopathy has been reported in 12–
33% of patients [15].
In conclusion, we demonstrate for the first time that
TIPS for refractory or recidivant ascites significantly im-
proves the QOL in patients with cirrhosis.
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